NEW YORK (GenomeWeb News) – UK biotech firm Epistem said today that it has received €1.5 million ($2 million) from the European Commission to develop point-of-care diagnostic tests for Hepatitis C as part of a €6 million, international project called the PoC HCV consortium.

The consortium aims to develop integrated genetic and protein biomarker tests for use in treating and monitoring HCV patients, as well as in clinical research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.